晚期非小细胞肺癌放疗联合免疫治疗的疗效比较
该研究基于香港医院管理局全港数据,纳入2010至2021年间接受免疫检查点抑制剂和放疗的晚期或难治性NSCLC患者。难治性患者中放疗后ICI维持与更长生存相关但无统计学意义。
要点
- 新诊断晚期NSCLC序贯放免较同期放免生存更优。
- 化疗与更长生存相关,但仅新诊断晚期患者中显著。
- 难治性NSCLC放疗后ICI维持有生存延长趋势但不显著。
核心结论
- 在新诊断晚期NSCLC中,序贯放免较同期放免与更长的真实世界OS相关。
- 化疗与新诊断晚期NSCLC患者更长的生存相关。
- 在难治性NSCLC中,放疗后ICI维持与数值上更长的生存相关但差异无统计学意义,化疗关联不明确。
- 上述发现为假设生成性,支持开展前瞻性随机研究以确定最佳序贯方式和全身治疗搭档。
研究设计与样本
- 本研究为基于香港医院管理局临床数据分析报告系统的全港队列研究(OCEANUS),覆盖超过90%人口。
主要发现
- 共3522例接受ICI的患者中,335例接受放疗,包括155例新诊断晚期和180例难治性NSCLC;247例(73.7%)为男性,中位年龄64岁(范围34-90)。
- 逆概率治疗加权分析产生相似估计。
临床怎么用
- 对于新诊断晚期NSCLC患者,序贯放免可能较同期放免带来更长的生存获益。
- 在新诊断晚期NSCLC中,联合化疗可能与更长的生存相关。
- 难治性NSCLC患者放疗后ICI维持的生存获益尚不明确,需个体化决策。
局限性
- 本研究为回顾性队列研究,存在残留混杂可能。
- 难治性NSCLC亚组样本量较小,ICI维持的生存差异未达统计学意义。
- 研究结果为假设生成性,需前瞻性随机研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal sequencing of radiotherapy (RT) combined with immunotherapy (iRT) and the value of chemotherapy remain undefined for advanced non-small cell lung cancer (NSCLC), where randomized data are limited. OBJECTIVE: To compare real-world overall survival (OS) between sequential and concurrent iRT in newly diagnosed advanced NSCLC, assess the effect of immune checkpoint inhibitor (ICI) maintenance after RT in refractory disease, and evaluate the association of chemotherapy with survival. DESIGN, SETTING, AND PARTICIPANTS: This is a territory-wide study (OCEANUS) based on the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System (more than 90% population coverage). Patients with NSCLC diagnosed from January 1, 2010, to December 31, 2021, who subsequently received iRT for advanced or refractory disease were included. Overlap weighting was the primary propensity score-weighted method, with inverse probability of treatment weighting used for sensitivity analysis. Data were analyzed from December 2024 to April 2025. EXPOSURES: Sequential vs concurrent iRT for newly diagnosed advanced NSCLC; RT with vs without ICI maintenance for refractory NSCLC; receipt of chemotherapy. MAIN OUTCOMES AND MEASURES: The primary outcome was real-world OS after landmark, estimated with weighted Kaplan-Meier and Cox models. When proportional hazards were violated (per Schoenfeld residuals), treatment effects were summarized using restricted mean survival time. RESULTS: Of 3522 patients who received ICIs, 335 received RT, including 155 with newly diagnosed advanced and 180 with refractory NSCLC. Of these, 247 (73.7%) were male, and the median (range) age was 64 (34-90) years. In newly diagnosed NSCLC, patients treated with sequential iRT had significant longer real-world OS than those treated with concurrent iRT (median, 20.3 months [95% CI, 13.3 to not reached] vs 16.0 months [95% CI, 8.3-30.0]; adjusted hazard ratio, 0.68; 95% CI, 0.47-0.99; P = .045). Chemotherapy was also associated with longer survival in patients with newly diagnosed advanced NSCLC. In refractory NSCLC, RT with ICI maintenance was associated with a numerically longer median real-world OS (11.2 months [95% CI, 7.9-20.6] vs 6.7 months [95% CI, 4.4-17.4]; P = .20). Addition of chemotherapy was not significant for real-world OS. Inverse probability of treatment weighting analyses produced similar estimates. CONCLUSIONS AND RELEVANCE: In this cohort study, sequential iRT was associated with longer survival than concurrent iRT in patients with newly diagnosed advanced NSCLC, and chemotherapy was associated with longer survival. In patients with refractory NSCLC who survived at least 90 days, RT with ICI maintenance resulted in nonsignificantly longer survival and an unclear association with chemotherapy. These findings are hypothesis generating and support prospective randomized studies to define optimal sequencing of iRT and use of systemic treatment partners.
引用
- Zhou H, Wang SC, Lee TTL, et al. Combination of Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2026. PMID: 41885834. doi:10.1001/jamaoncol.2026.0392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。